In cancers such as ovarian, breast, gastric, and small cell lung cancer (SCLC), high SLFN11 expression consistently predicts better outcomes in patients treated with DNA-targeting chemotherapy (10–12, 37, 44). Here, SLFN11 is linked to small cell lung carcinoma.